Viridian Therapeutics, Inc.
VRDN
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the trā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$18.92
Price-4.93%
-$0.98
1Y
Price
Market Cap
$1.703b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-86429.5%
EBITDA Margin-91178.0%
Net Profit Margin-18177.3%
Free Cash Flow Margin-86429.5%
EBITDA Margin-91178.0%
Net Profit Margin-18177.3%
Free Cash Flow MarginRevenue
$70.918m
+23359.9%
1y CAGR+7757.9%
3y CAGR+5808.4%
5y CAGREarnings
-$360.590m
-26.9%
1y CAGR-41.2%
3y CAGR-46.8%
5y CAGREPS
-$3.48
+16.6%
1y CAGR+1.9%
3y CAGR+11.8%
5y CAGRBook Value
$636.008m
$789.017m
Assets$153.009m
Liabilities$51.174m
DebtDebt to Assets
6.5%
-0.1x
Debt to EBITDAFree Cash Flow
-$303.824m
-18.9%
1y CAGR-46.8%
3y CAGR-53.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company